Advertisement
LLY or REGN or VRTX
Which Stock Would AI Choose? Eli Lilly and Company (LLY) vs. Regeneron Pharmaceuticals (REGN) vs. Vertex Pharmaceuticals (VRTX) Stock Comparison
Key Takeaways
- LLY leads in market capitalization at over $900 billion but has faced recent downward pressure, declining about 5-6% in the past month amid competition in obesity treatments.
- REGN demonstrates relative stability with year-to-date gains around 1-2%, supported by strong Dupixent sales and Eylea HD growth, trading at a forward P/E of approximately 17x.
- VRTX shows resilience in cystic fibrosis dominance, with modest YTD performance near flat to positive, backed by recent earnings beats and a forward P/E around 24x.
- All three biotech leaders reported solid Q4 2025 earnings, with revenue growth driven by key products, though LLY faces higher valuation multiples compared to peers.
- Recent market activity highlights REGN's outperformance over the past year at about 11%, versus slight declines for VRTX and moderated gains for LLY.
- Sector sentiment favors diversified pipelines, with REGN and VRTX appearing more attractively valued relative to growth prospects.
Introduction
This stock comparison examines Eli Lilly and Company (LLY), Regeneron Pharmaceuticals (REGN), and Vertex Pharmaceuticals (VRTX), three prominent biotech firms navigating a dynamic healthcare landscape. These companies specialize in innovative therapies for metabolic, ophthalmic, immunologic, and genetic diseases, making them relevant for growth-oriented investors and traders seeking exposure to pharmaceuticals with strong pipelines. Recent earnings beats and product momentum provide context for relative performance, aiding decisions on market positioning amid sector volatility.
LLY Overview and Recent Performance
Eli Lilly and Company (LLY) is a leading pharmaceutical giant focused on diabetes, obesity, oncology, and immunology, with blockbuster drugs like Mounjaro and Zepbound driving growth. In recent market activity, LLY shares have traded around $990, reflecting a roughly 5-6% decline over the past month despite robust Q4 2025 earnings that exceeded expectations on revenue and EPS. Sentiment has been influenced by competitive pressures in the GLP-1 obesity space and broader equity corrections, though partnerships to expand access to treatments like Zepbound signal ongoing demand. Year-to-date, the stock is down approximately 8%, with projections for strong 2026 revenue growth underscoring long-term potential.
REGN Overview and Recent Performance
Regeneron Pharmaceuticals (REGN) develops therapies for eye diseases, cancer, and inflammatory conditions, highlighted by Eylea HD and Dupixent collaborations. Shares have hovered near $760 in recent weeks, showing stability with minor fluctuations and year-to-date gains of about 1-2%. Q4 2025 results beat estimates, with revenues up 3% year-over-year to $3.88 billion, bolstered by Dupixent strength offsetting Eylea headwinds. Positive analyst initiations and a recent dividend increase have supported sentiment, contributing to roughly 11% one-year returns amid a defensive positioning in biotechnology.
VRTX Overview and Recent Performance
Vertex Pharmaceuticals (VRTX) dominates cystic fibrosis treatments with products like Trikafta, expanding into pain management and gene therapies. Trading around $457 lately, VRTX has experienced modest volatility, with shares down about 3% in recent sessions but holding year-to-date gains near flat to 1%. Q4 2025 earnings slightly missed EPS consensus at $5.03 but beat on revenue at $3.19 billion, up 9.5% year-over-year, fueled by CF portfolio growth. Positive trial data from Journavx has bolstered outlook, though broader sector pressures have tempered momentum.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases a curated selection of over 25 high-performing AI trading bots from Tickeron's extensive library of hundreds of bots that trade thousands of tickers across stocks, ETFs, and crypto. These bots employ diverse strategies like AI/ML pattern recognition, technical, and fundamental analysis, with timeframes from 5 minutes to 60 minutes. Top performers display annualized returns ranging from +32% to +218%, win rates of 61-94%, and profit factors up to 25.83, adapting to current volatility in sectors like aerospace, infrastructure, and tech. Examples include the AeroDefense ITA bot at +32% annualized with 80% win rate on ITA ETF, and multi-ticker bots yielding +135% on commodities and semis. Traders can explore these for real-time signals and copy trading suited to market conditions. Visit Trending AI Robots to review performance and deploy.
Head-to-Head Comparison
LLY, REGN, and VRTX operate in overlapping biotech domains but diverge in business models: LLY leverages broad pharma scale with obesity blockbusters, while REGN and VRTX emphasize specialized biologics and gene therapies. Growth drivers contrast LLY's high-volume GLP-1 momentum against REGN's Dupixent royalties and VRTX's CF monopoly. Recent momentum favors REGN's stability over LLY's pullback and VRTX's steadiness. Risk factors include LLY's competition exposure, REGN's Eylea erosion, and VRTX's pipeline reliance. Valuation sensitivity shows REGN at a forward P/E of ~17x as most attractive, versus ~24x for VRTX and higher multiples for LLY. Market sentiment tilts toward REGN and VRTX for relative value in a cautious biotech environment.
Tickeron AI Verdict
Tickeron’s AI currently favors REGN based on trend consistency, attractive valuation at a forward P/E around 17x, stable recent performance, and diversified catalysts like Dupixent growth offsetting headwinds. While LLY offers superior scale and VRTX pipeline promise, REGN's relative positioning suggests higher probability of outperformance in the near term amid biotech volatility.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
LLY’s FA Score shows that 2 FA rating(s) are green whileREGN’s FA Score has 1 green FA rating(s), and VRTX’s FA Score reflects 1 green FA rating(s).
- LLY’s FA Score: 2 green, 3 red.
- REGN’s FA Score: 1 green, 4 red.
- VRTX’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
LLY’s TA Score shows that 5 TA indicator(s) are bullish while REGN’s TA Score has 4 bullish TA indicator(s), and VRTX’s TA Score reflects 3 bullish TA indicator(s).
- LLY’s TA Score: 5 bullish, 3 bearish.
- REGN’s TA Score: 4 bullish, 5 bearish.
- VRTX’s TA Score: 3 bullish, 6 bearish.
Price Growth
LLY (@Pharmaceuticals: Major) experienced а +2.10% price change this week, while REGN (@Biotechnology) price change was +0.79% , and VRTX (@Biotechnology) price fluctuated +1.84% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -0.87%. For the same industry, the average monthly price growth was -3.24%, and the average quarterly price growth was +6.57%.
The average weekly price growth across all stocks in the @Biotechnology industry was +2.26%. For the same industry, the average monthly price growth was -2.98%, and the average quarterly price growth was +6.73%.
Reported Earning Dates
LLY is expected to report earnings on Apr 30, 2026.
REGN is expected to report earnings on Apr 29, 2026.
VRTX is expected to report earnings on May 04, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (-0.87% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
@Biotechnology (+2.26% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| LLY | REGN | VRTX | |
| Capitalization | 853B | 81.2B | 114B |
| EBITDA | 31.7B | 5.82B | 4.87B |
| Gain YTD | -10.970 | -0.401 | -1.451 |
| P/E Ratio | 41.62 | 18.51 | 29.16 |
| Revenue | 65.2B | 14.3B | 12B |
| Total Cash | 7.27B | 8.61B | 6.61B |
| Total Debt | 42.5B | 2.71B | 2.03B |
LLY | REGN | VRTX | ||
|---|---|---|---|---|
OUTLOOK RATING 1..100 | 10 | 13 | 4 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 68 Overvalued | 3 Undervalued | 81 Overvalued | |
PROFIT vs RISK RATING 1..100 | 19 | 72 | 33 | |
SMR RATING 1..100 | 13 | 53 | 39 | |
PRICE GROWTH RATING 1..100 | 55 | 46 | 59 | |
P/E GROWTH RATING 1..100 | 88 | 37 | 49 | |
SEASONALITY SCORE 1..100 | 50 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
REGN's Valuation (3) in the Biotechnology industry is somewhat better than the same rating for LLY (68) in the Pharmaceuticals Major industry, and is significantly better than the same rating for VRTX (81) in the Biotechnology industry. This means that REGN's stock grew somewhat faster than LLY’s and significantly faster than VRTX’s over the last 12 months.
LLY's Profit vs Risk Rating (19) in the Pharmaceuticals Major industry is in the same range as VRTX (33) in the Biotechnology industry, and is somewhat better than the same rating for REGN (72) in the Biotechnology industry. This means that LLY's stock grew similarly to VRTX’s and somewhat faster than REGN’s over the last 12 months.
LLY's SMR Rating (13) in the Pharmaceuticals Major industry is in the same range as VRTX (39) in the Biotechnology industry, and is somewhat better than the same rating for REGN (53) in the Biotechnology industry. This means that LLY's stock grew similarly to VRTX’s and somewhat faster than REGN’s over the last 12 months.
REGN's Price Growth Rating (46) in the Biotechnology industry is in the same range as LLY (55) in the Pharmaceuticals Major industry, and is in the same range as VRTX (59) in the Biotechnology industry. This means that REGN's stock grew similarly to LLY’s and similarly to VRTX’s over the last 12 months.
REGN's P/E Growth Rating (37) in the Biotechnology industry is in the same range as VRTX (49) in the Biotechnology industry, and is somewhat better than the same rating for LLY (88) in the Pharmaceuticals Major industry. This means that REGN's stock grew similarly to VRTX’s and somewhat faster than LLY’s over the last 12 months.
| LLY | REGN | VRTX | |
|---|---|---|---|
| RSI ODDS (%) | 1 day ago 74% | N/A | N/A |
| Stochastic ODDS (%) | 1 day ago 59% | 1 day ago 61% | 1 day ago 70% |
| Momentum ODDS (%) | 1 day ago 65% | 1 day ago 62% | 1 day ago 47% |
| MACD ODDS (%) | 1 day ago 62% | 1 day ago 74% | 1 day ago 50% |
| TrendWeek ODDS (%) | 1 day ago 70% | 1 day ago 54% | 1 day ago 42% |
| TrendMonth ODDS (%) | 1 day ago 57% | 1 day ago 61% | 1 day ago 37% |
| Advances ODDS (%) | 1 day ago 71% | 10 days ago 64% | 1 day ago 62% |
| Declines ODDS (%) | 5 days ago 54% | 22 days ago 50% | 4 days ago 42% |
| BollingerBands ODDS (%) | 1 day ago 72% | 1 day ago 49% | 4 days ago 74% |
| Aroon ODDS (%) | 1 day ago 56% | 1 day ago 69% | 1 day ago 28% |
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| RDVY | 72.63 | 0.65 | +0.90% |
| First Trust Rising Dividend Achiev ETF | |||
| GRX | 9.22 | 0.03 | +0.33% |
| Gabelli Healthcare & Wellness Trust (The) | |||
| TBX | 28.02 | 0.03 | +0.11% |
| ProShares Short 7-10 Year Treasury | |||
| TSEL | 25.68 | -0.02 | -0.08% |
| Touchstone Sands Capital US Sel Gr ETF | |||
| EWX | 69.13 | -0.07 | -0.10% |
| State Street® SPDR® S&P® EM Sm Cp ETF | |||
LLY and
Correlation & Price change
A.I.dvisor indicates that over the last year, LLY has been loosely correlated with MRK. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if LLY jumps, then MRK could also see price increases.